BRCA1 and cancer: Multigene panel tests increased the diagnostic yield, with almost a quarter of the patients diagnosed with pathogenic mutations harboring mutations in non-BRCA1/2 genes that could account for their personal/family cancer history, although VUS rate was three times higher than with targeted gene testing.